FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (Nasdaq: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, announced today its plans to bring the Sonatherm 600, (“Sonatherm”) used for high intensity focused ultrasound (“HIFU”) treatment of soft tissue, including cancerous tissue in the kidney, into China. The Sonatherm has been developed by Misonix in connection with the worldwide rights that Misonix acquired from Focus Surgery, Inc, a major HIFU developer. As part of the Company’s strategy to enter into the world’s most populous country, a distribution agreement was formed with China-based Acton Medical Device Corp. (“Acton”) of Guangzhou. Acton has a sales team of 156 people covering over 20 provinces.
